Disappointment For Novartis As England’s NICE Says No To Migraine Drug Again
Doubts linger over Aimovig's cost effectiveness
New cost-effectiveness analyses and an improved deal for Aimovig have failed to change the health technology assessment body's mind about routine funding for the migraine prevention drug.
You may also be interested in...
Following two previous rejections by the UK’s health technology assessment body and an appeal, Aimovig is now available on the National Health Service for preventing migraine.
Scotland’s health technology appraisal body has OKd Novartis’s Aimovig for migraines. England’s NICE has postponed a meeting on the drug after a large number of comments were received following the institute’s initial knockback.
In contrast with the five COVID-19 vaccines that are approved in the EU under conditional marketing authorizations, the European Medicines Agency has recommended that Valneva’s vaccine receive a standard approval.